Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study found that ultraviolet light-enhanced visualization can detect subtle skin changes linked to carotene and vitamin A deficiency, which improved with dietary correction in deficient individuals.

In this case study, a patient experienced darkening of hair color after taking acitretin, an oral retinoid known for potentially causing alopecia, marking a rare and undocumented phenomenon.

This case report describes a 52-year-old male with folliculitis decalvans, initially resembling lupus vulgaris, who was successfully treated with minocycline and clarithromycin.

In this study, a combined treatment of Androcur and Diane improved acne, seborrhea, hirsutism, and androgenic alopecia in women to varying degrees over two years.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

The EADV Task Force on Hair Diseases reviewed existing literature and clinical experience to propose diagnostic and therapeutic recommendations for managing folliculitis decalvans, highlighting oral antibiotics, glucocorticosteroids, isotretinoin, and various systemic and topical therapies as key options for managing inflammation and preventing further hair loss.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This study found that the aromatic retinoic acid derivative Ro 10-9359 provided excellent results in 64% of severe psoriasis patients, especially in those with erythrodermic and pustular types, though relapses and side effects were noted.

This study demonstrated that litifilimab significantly reduced disease activity in cutaneous lupus erythematosus by Week 16, with improvements most notable in sunlight-exposed skin areas.

This study found that combining topical calcipotriol with intralesional autologous PRP injection significantly reduced Severity of Alopecia Tool scores in patients with alopecia areata, more effectively than either treatment alone.

Gabapentin helps with scalp itch, dutasteride works for frontal fibrosing alopecia, and more research is needed for better PCA treatments.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This case report suggests acitretin as a potential treatment for pseudoainhum, following the successful resolution of the condition in a patient with palmoplantar keratoderma and congenital alopecia.

This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

The excimer laser may help hair regrow in alopecia areata patients.

This study found that the ThriveCo Anti-Dandruff Pre-Shampoo Treatment, containing ZenscalpinTM, significantly reduced dandruff by 54.79% after 8 days and improved scalp health, with most participants reporting reduced flaking, dryness, and itchiness, and no noted adverse events.

In this randomized control trial, researchers reported that topical calcipotriol was more effective than topical tacrolimus in promoting hair growth for patients with alopecia areata over a 6-month period, with a statistically significant difference in efficacy.